Safety issues in hormonal therapy

doi:10.3969/j.issn.1006-7795.2013.04.001

Abstract

Abstract:

Safety issues in hormonal therapy have been discussed in recent years especially in the field of hormone replacement therapy(HRT). The most important study Women's Health Initiative(WHI) has been stopped in 2002 due to increased risk of venous thromboembolism, myocardial infarction, stroke and breast cancer. This overview will concentrate on these main risks. There are options of different HRT regimens to minimize these risks. Especially plausible is the use of minimal dosages of transdermal administration avoiding first liver passage which should reduce hepatic and cardiovascular risks, which, however, is not based on placebo-controlled studies. For breast cancer development, first fear of most women, further research on the two main mechanisms are most important-proliferation effects and conditions for potential genotoxic estrogen metabolites. To individualize hormonal therapy also preexisting risks have to be considered, and with early start, within a "window of opportunity", most patients will benefit from HRT if indicated.

Key words: hormonal therapy, safety issues, breast cancer

Alfred O. Mueck, Ruan Xiangyan. Safety issues in hormonal therapy[J]. Journal of Capital Medical University, 2013, 34(4): 483-491.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.04.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I4/483

References

[1] Marchbanks P A, McDonald J A, Wilson H G, et al. Oral contraceptives and the risk of breast cancer[J]. N Engl J Med, 2002,346(26):2025-2032.

[2] Hannaford P C, Selvaraj S, Elliott A M, et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study[J]. BMJ, 2007,335(7621):651.

[3] WHI Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women[J]. JAMA, 2002,288(3):321-333.

[4] WHI Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy[J]. JAMA, 2004,291(14):1701-1712.

[5] WHI Investigators. Estrogen plus progestin and the risk of coronary heart disease[J]. N Engl J Med, 2003,349(6):523-534.

[6] WHI Investigators. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause[J]. JAMA, 2007,297(13):1465-1477.

[7] Ortmann O(Leitlinienkoordination). Hormontherapie in der Peri-und Postmenopause. Kurzversion der interdisziplinären S3-Leitlinie[J]. Frauenarzt, 2009,50(11):840-851.

[8] WHI Investigators. Conjugated equine estrogens and coronary heart disease[J]. Arch Intern Med, 2006,166(3):357-365.

[9] Moorjani S, Dupont A, Labrie F. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral vesrsus transdermal administration of estrogens[J]. J Clin Endocrinol Metab, 1991,73(2):373-379.

[10] Scarabin P Y, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial[J]. Arterioscler Thromb Vasc Biol, 1997,17(11):3071-3078.

[11] Godsland I F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: analysis of studies published from 1974-2000[J]. Fertil Steril, 2001,75(5):898-915.

[12] Wakatsuki A, Okatani Y, Ikenoue N, et al. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women[J]. Circulation, 2002,106(14):1771-1776.

[13] Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women[J]. Thromb Haemost, 2001,85(4):619-625.

[14] Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women[J]. Circulation, 2002,106(10):1224-1228.

[15] Modena M G, Bursi F, Fantini G, et al. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen[J]. Am J Med, 2002,113(4):331-334.

[16] Sumino H, Ichikawa S, Ohyama Y, et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women[J]. Am J Cardiol, 2005,96(1):148-153.

[17] Lokkegaard E, Andreasen A H, Jacobsen R K, et al. Hormone therapy and risk of myocardial infarction: a national register study[J]. Eur Heart J, 2008,29(21):2660-2668.

[18] Clarke S C, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study[PHASE][J]. BJOG, 2002,109(9):1056-1062.

[19] Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone repacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial(EVTET)[J]. Thromb Haemost, 2000,84(6):961-967.

[20] Hoibraaten E, Mowinckel M C, de Ronde H, et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial[J]. Br J Haematol, 2001,115(2):415-420.

[21] Tans G, van Hylckama Vlieg A, Thomassen M C, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women[J]. Br J Haematol, 2003,122(3):465-470.

[22] Hoibraaten E, Mowinckel M C, de Ronde H, et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial[J]. Br J Haematol, 2001,115(2):415-420.

[23] Post M S, Christella M, Thomassen L G, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women[J]. Arterioscler Thromb Vasc Biol, 2003,23(6):1116-1121.

[24] Scarabin P Y, Oger E, Plu-Bureau G(for the ESTHER Study Group). Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk[J]. Lancet, 2003,362(9382):428-432.

[25] Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism. Results from the E3N Cohort Study[J]. Thromb Vasc Biol, 2010,30(2):340-345.

[26] Straczek C, Oger E, de Jonage-Canonico M B Y, et al(for the ESTHER Study Group). Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration[J]. Circulation, 2005,112(22):3495-3500.

[27] Canonico M, Plu-Bureau G, Lowe G D O, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: a systematic review and meta-analysis[J]. BMJ, 2008,336(7665):1227-1231.

[28] Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administation and progestogens: The ESTHER Study[J]. Circulation, 2007,115(7):840-845.

[29] Beral V(Collaborative Group on Hormonal Factors in Breast Cancer). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer[J]. Lancet, 1997,350(9084):1047-1059.

[30] Seeger H, Mueck A O. HRT and breast cancer caused: Caused by progestogens?[J]. J Steroid Biochem Mol Biol, 2008,109(2):11-15.

[31] WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women[J]. JAMA, 289(24):3243-3253.

[32] WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy[J]. JAMA, 2006,295(14):1647-1657.

[33] Cogliano V, Grosse Y, Baan R, et al(WHO International Agency for Research on Cancer, IARC). Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment[J]. Lancet Oncol, 2005,6(4):552-553.

[34] Rogan E G, Badawi A F, Devanesan P D, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer[J]. Carcinogenesis, 2003,24(4):697-702.

[35] Mueck A O, Seeger H. Breast cancer: are oestrogen metabolites carcinogenic?[J]. Maturitas, 2007,57(1):42-46.

[36] Dietel M, Lewis M A, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review[J]. Hum Reprod, 2005,20(8):2052-2060.

[37] Mueck A O, Seeger H, Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition[J]. Climacteric, 2003,6(3):221-227.

[38] Krämer E, Seeger H, Krämer B, et al. The effects of progesterone and synthetic progestogens on growth factor and estradiol treated human cancerous and non-cancerous breast cells[J]. Menopause, 2005,129(1):468-474.

[39] Neubauer H, Adam G, Seeger H, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells[J]. Climacteric, 2009,12:230-239.

[40] de Lignieres B, de Vathaire F, Fournier S, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3 175 women[J]. Climacteric, 2002,5(4):332-340.

[41] Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone therapies: results from the E3N cohort study[J]. Breast Cancer Res Treat, 2008,107(1):103-111.

[42] Opatrny L, Dell'Aniello S, Assouline S, et al. Hormone replacement therapy and variations in the risk of breast cancer[J]. BJOG, 2008,115(1):169-175.

[43] Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy[J]. Obstet Gynecol, 2009,113(1):65-73.

[44] Seeger H, Mueck A O, Lippert T H. Effect of norethisterone acetate on estradiol metabolism in postmenopausal women[J]. Horm Metab Res, 2000,32(10):436-439.

[45] Henderson B E, Feigelson H S. Hormonal carcinogenesis[J]. Carcinogenesis, 2000,21(3):427-433.

[46] Seeger H, Wallwiener D, Krämer E, et al. Comparison of possible carcinogenic estradiol metabolites: Effects on proliferation, apoptosis and metastasis of human breast cancer cells[J]. Maturitas, 2006,54(1):72-77.

[47] Liehr J G, Ricci M J. 4-Hydroxylation of estrogens as marker of human mammary tumors[J]. Proc Natl Acad Sci USA, 1996,93(8):3294-3296.

[48] Chakravarti D, Mailander P C, Higginbotham S. The catechol estrogen-3, 4-quinone metabolite induces mutations in the mammary gland of ACI rats[J]. Proc Am Assoc Cancer Res, 2003,44(4):180-186.

[49] Lippert T H, Seeger H, Mueck A O. Estradiol metabolism during oral and transdermal estradiol replacement therapy in the postmenopause[J]. Horm Metab Res, 1998,30(9):598-600.

[50] Bolton J L, Pisha E, Zhang F, et al. Role of quinoids in estrogen carcinogenesis[J]. Chem Res Toxicol, 1998,11(10):1113-1127.

[51] Liehr J G, Roy D. Free radical generation by redox cycling of estrogens[J]. Free Radic Biol Med, 1990,8(4):415-423.

[52] Mueck A O, Seeger H. Smoking, estradiol metabolism and hormone replacement therapy[J]. Drug Res, 2003,53(1):1-11.

[53] Berstein L M, Tsyrlina E V, Kolesnik O S, et al. Catecholestrogens excretion in smoking and non-smoking postmenopausal women receiving estrogen replacement therapy[J]. J Steroid Biochem Mol Biol, 2000,72(3-4):143-147.

[54] Dunning A M, Healey C S, Pharoah P D P, et al. A systematic review of genetic polymorphisms and breast cancer risk[J]. Cancer Epidemiol Biomarkers Prev, 1999,8(16):843-854.

[55] Bugano D D, Conforti-Froes N, Yamaguchi N H, et al. Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review[J]. Eur J Gynaecol Oncol, 2008,29(4):313-320.